Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Shingrix

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Lilly launches global Alzheimer’s campaign with Julianne Moore

The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

- PMLiVE

TRIMTECH Therapeutics establishes Scientific Advisory Board

Alessio Ciulli has been appointed as Chair of the board

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links